Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, largely due to its poor response to conventional chemotherapy. The successful development of Kirsten rat sarcoma virus (KRAS) inhibitors raised new hopes for effective targeted therapy, given that KRAS mutations represent the predominant oncogenic driver in PDAC. However, clinical and preclinical studies have rapidly revealed both primary and acquired resistance following KRAS inhibitor monotherapy. This study aimed to investigate the mode of action of the KRASG12D inhibitor MRTX1133 and to explore combination strategies to overcome resistance. In conventional and patient-derived KRASG12D-mutant cell lines, nanomolar concentrations of MRTX1133 effectively reduced cell viability and clonogenic growth in CellTiter-Glo®️ assays and clonogenic growth assays. Based on differential sensitivity, cell lines were categorized as resistant or sensitive. Furthermore, the selective, mutation-specific effect of MRTX1133 was confirmed by evaluation in KRASG12C-mutant cell lines. Comparative analyses of the cell viability between 2D patient-derived cell lines (PDCL) and their matched 3D organoids revealed distinct responses to MRTX1133. Protein analysis demonstrated that MRTX1133 inhibited phosphorylation the extracellular-signal regulated kinase (ERK), a key downstream factor of KRAS signaling. Sensitivity to MRTX1133 correlated with a low baseline ratio of phosphorylated to total ERK. Flow cytometry revealed treatment-induced G1-phase cell cycle arrest in the sensitive conventional Panc 05.04 cell line. A combinatorial drug screen using resistant models (AsPC-1 and Pan16T-PDCL) identified strong synergy between MRTX1133 and inhibitors targeting the epidermal growth factor receptor axis, consistent with published data. Notably, a previously unrecognized synergism between MRTX1133 and the Menin-MLL1 interaction inhibitor MI-503 was discovered. This was validated in long-term clonogenic and live-cell assays in AsPC-1, and in the in situ resistance assay in both cell lines. However, the synergistic effect could not be reproduced in short-term assays or other KRASG12D-mutant cell lines. These findings highlight the potential of rational combination therapies for KRASG12D-mutant PDAC and point to a previously less explored mechanistic link between KRAS signaling and the Menin-MLL1 complex that warrants further genetic and functional investigation.